Please login to the form below

Not currently logged in
Email:
Password:

Xceleron and Organon sign microdose study agreement

Xceleron collaborates with Organon on a three-compound human microdose study focusing on candidate selection for further clinical development

UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on candidate selection for further clinical development.

The three selected drug candidates are all compounds from Organon' gynaecological R&D activities. The purpose of the human microdose study is to assess all important pharmacokinetic properties of the compounds, while confirming the scalability of the microdose to pharmacological dose for these compounds.

Xceleron will use its Accelerator Mass Spectrometry analytical technology to determine human plasma concentrations after microgram administration of the various drug candidates.

Xceleron' founder and CEO Professor Colin Garner said: "We are delighted that Organon has further demonstrated its willingness to adopt innovative approaches to drug development and are proud to add them to Xceleron' rapidly growing, international portfolio of human microdose supporters."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics